Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?
23/10 17:00
Earlier this month, Merck (NYSE: MRK) announced it was ending clinical trials of its antiviral pill candidate for treating COVID-19, molnupiravir, on account of the potential therapy's high level of effectiveness. The pill could cut the risk of hospitalization or death by as much...